Hosokawa K, Yamazaki H, Mochizuki K, Ohata K, Ishiyama K, Hayashi T, Kondo Y, Sugimori N, Okumura H, Takami A, Nakao S
Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Transpl Infect Dis. 2012 Apr;14(2):184-7. doi: 10.1111/j.1399-3062.2011.00670.x. Epub 2011 Sep 28.
Trichosporon fungemia is a rare and fatal fungal infection that occurs in patients with prolonged neutropenia associated with hematologic malignancies. A 21-year-old male developed Trichosporon fungemia during remission induction therapy for acute myeloid leukemia (AML). Although two courses of induction therapy failed to induce a remission of AML, combination therapy with voriconazole and liposomal amphotericin B (L-AmB) followed by monocyte colony-stimulating factor ameliorated the Trichosporon fungemia and enabled the patient to receive reduced-intensity bone marrow transplantation (BMT) from his human leukocyte antigen-A one-locus mismatched mother. The patient achieved a durable remission after BMT without exacerbation of Trichosporon fungemia. The combination therapy with voriconazole and L-AmB may therefore be useful in controlling Trichosporon fungemia associated with prolonged neutropenia after remission induction therapy for AML.
毛孢子菌血症是一种罕见且致命的真菌感染，发生于与血液系统恶性肿瘤相关的长期中性粒细胞减少患者中。一名21岁男性在急性髓系白血病（AML）缓解诱导治疗期间发生了毛孢子菌血症。尽管两个疗程的诱导治疗未能诱导AML缓解，但伏立康唑和脂质体两性霉素B（L-AmB）联合治疗，随后使用单核细胞集落刺激因子改善了毛孢子菌血症，并使患者能够接受来自其人类白细胞抗原-A一位点不匹配母亲的低强度骨髓移植（BMT）。患者在BMT后实现了持久缓解，且毛孢子菌血症未加重。因此，伏立康唑和L-AmB联合治疗可能有助于控制AML缓解诱导治疗后与长期中性粒细胞减少相关的毛孢子菌血症。
